Cargando…
Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
BACKGROUND: Over the past decade, there has been increasing availability of novel therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to compare the uptake of systemic therapy (ST) before and after the availability of targeted t...
Autores principales: | Leung, Bonnie, Shokoohi, Aria, Al-Hashami, Zamzam, Moore, Sara, Pender, Alexandra, Wong, Selina K., Wang, Ying, Wu, Jonn, Ho, Cheryl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114445/ https://www.ncbi.nlm.nih.gov/pubmed/37076834 http://dx.doi.org/10.1186/s12885-023-10800-x |
Ejemplares similares
-
Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
por: Shokoohi, Aria, et al.
Publicado: (2021) -
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023) -
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022) -
Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022) -
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)